Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
It has been a fantastic #AES2021 and we are so thankful to everyone’s unified ambition to support the #epilepsy community. So much has been achieved but there are so many more unmet needs to consider. We spoke to Prof Schulze-Bonhage on his opinion on the
— UCB News (@ucb_news) 07.12.2021 -
We spoke to Ludovic Ampe, Co-Founder at @neuroventis to find out his opinion on the best way to support and empower people living with #epilepsy. https://t.co/iDYYNFOMjJ
— UCB News (@ucb_news) 05.12.2021 -
While there have been significant developments in #epilepsycare, more can be done to holistically manage the disease. We spoke to @byteflies on their opinions of the greatest challenges faced by people living with #epilepsy. https://t.co/TgkQHW0hNa
— UCB News (@ucb_news) 04.12.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
